Novartis CEO Vasant Narasimhan on Transforming a 250-Year-Old Company

a16z PodcastVasant Narasimhan — CEO at NovartisFeb 16, 202658 min

Novartis CEO Vasant Narasimhan reveals how he dismantled a 250-year-old conglomerate to unlock $180 billion in shareholder value, spinning off multiple business units to focus purely on innovative medicines. The conversation offers rare insight into how AI is already transforming drug discovery workflows from months to minutes, while Narasimhan explains why the first fully AI-generated drug is still a decade away despite current hype.

Key takeaways

•Conglomerates destroy value when business units have fundamentally different return profiles—Novartis unlocked $180B by spinning off consumer health, generics, and devices to focus solely on pharmaceuticals.
•AI is already accelerating drug discovery research from six-month timelines to minutes, but the first purely AI-generated drug candidate won't reach market for another 8-10 years due to clinical trial requirements.
•Platform technologies like cell/gene therapies create competitive moats by allowing companies to rapidly deploy the same underlying technology across multiple diseases without starting from scratch.
•The US risks losing clinical trial competitiveness unless it builds standardized platform networks that eliminate the contracting and setup delays that slow trial initiation compared to other regions.

Listen to full episode

0:00

corporate-transformation pharma ai-drug-discovery spinoffs platform-technologies

Best moment

6:34· 33sframework

Why Novartis had to break up its 250-year-old business model

“But then the second thing is you ask, what is a company fundamentally great at?”

6:34 / 7:07

When you look at it, the return on capital, of course, varies tremendously between a consumer health business, a generics business, a device business, and a pharmaceuticals business. And we were often forced to say we have to sub optimize the pharmaceutical business to invest in the other businesses, or I'd have to say no Mhmm. To very good decisions for the Sandoz business to support the pharmaceuticals business. So I think there was this strategic misallocation of capital. But then the second thing is you ask, what is a company fundamentally great at? Novartis is, I think, really good at discovering and developing

Full clip page →

6 clips

Ordered by timestamp. Jump to the moment you care about.

a16z Podcast · Vasant Narasimhan

Novartis CEO explains the radical rethink that transformed a 250-year-old pharma giant

Novartis CEO Vasant Narasimhan describes the strategic decision to transform the company into a pure-play biopharmaceuticals business. He explains how they exited the consumer health business through a GSK joint venture and focused on specific therapeutic areas they believed would have the greatest impact.

4:55 - 5:2631s

corporate-transformation business-focus pharma-strategy

a16z Podcast · Vasant Narasimhan

How Novartis CEO unlocked $180 billion by breaking up a 250-year-old company

Novartis CEO Vasant Narasimhan explains how he transformed the pharmaceutical giant from a sprawling conglomerate into four focused companies through strategic spinoffs and divestitures. He details the spin-offs of Alcon and Sandoz, plus the sale of their Roche stake, which collectively unlocked nearly $180 billion in value.

5:26 - 5:4518s

corporate-restructuring spinoffs value-creation

a16z Podcast · Vasant Narasimhan

Why Novartis had to break up its 250-year-old business model

Novartis CEO explains how running multiple business units with different economics forced strategic capital misallocation. He describes the tough trade-offs between optimizing their pharmaceutical business versus investing in generics and devices, ultimately leading to a major corporate restructuring.

6:34 - 7:0733s

capital-allocation corporate-restructuring business-focus

a16z Podcast · Vasant Narasimhan

Why the first AI-generated drug won't exist for another decade

Novartis CEO explains the harsh reality behind AI drug discovery hype - while everyone expects breakthrough results in two years, the first purely AI-generated drug candidate won't emerge for 8-10 years. He shares how Novartis is partnering with Isomorphic Labs to tackle previously 'undruggable' targets using AlphaFold technology.

33:18 - 33:4729s

ai-drug-discovery pharmaceutical-timelines undruggable-targets

a16z Podcast · Vasant Narasimhan

How Novartis cut 6-month research from months to minutes using AI

Novartis CEO explains how their AI platform called Foundry has transformed their research capabilities, with 3,000 scientists now using AI models to extract data from their data lake in minutes instead of the six months it used to take. He describes this as an incredible leap in pharmaceutical research efficiency that took years to develop and implement.

35:13 - 35:3320s

ai-transformation data-analytics pharma-research

a16z Podcast · Vasant Narasimhan

If we could get more platforms in place where you could just go right into a particular disease without having to recontract and redo everything, you could generate the data a lot faster. Those kind of networks need to get scaled if the US wants to remain competitive.

Identifies a specific bottleneck (contracting/IRB reviews) that slows US drug development and connects it to national competitiveness. Practical insight into regulatory reform with clear competitive implications.

43:12 - 43:3322s

From the blog

Clypt vs Opus Clip: Why Generic AI Clippers Fail on VC Podcasts

8 min read

Want clips like this for your podcast?

We find your top 5-8 clips, write the hooks, and deliver ready-to-post content. First 2 episodes are free.

Get 2 Episodes Clipped Free